MUTATION STATUS AND IMMUNOHISTOCHEMICAL
CORRELATION OF EGFR MUTATIONS IN
GASTROINTESTINAL STROMAL TUMORS
Ozkayalar H1, Ergoren MC2,3,*, Tuncel G2,3, Kurt S4, Cevik E4, Ozemri Sag S4,
Yilmaz Ozguven B5, Kabukcuoglu F5, Mocan G1,2, Temel ŞG4,6,7,*
*Corresponding Author: Associate Professor Mahmut C. Ergoren, Department of Medical Genetics,
Faculty of Medicine, Near East University, Near East Boulevard, 99138 Nicosia, Northern Cyprus.
Tel.: +90-392-444-0535. Fax: +90-392-223-6461. E-mail: mahmucerkez.ergoren@neu.edu.tr. And/or:
Associate Professor Sehime G. Temel, Department of Medical Genetics, Faculty of Medicine, Bursa
Uludag University, Özlüce Görüjke Kampüsü, 16059 Nilüfer, Bursa, Turkey. Tel.: +90-224-295-0000.
Fax: +90-224-295-0019. E-mail: sehime@uludag.edu.tr.
page: 67
|
|
REFERENCES
1. Miettinen M, Lasota J. Gastrointestinal stromal
tumors: Pathology and prognosis at different sites.
Semin Diagn Pathol. 2006; 23(2): 70-83.
2. DeMatteo RP, Lewis JJ, Leung D, Mudan SS, Woodruff
JM, Brennan MF. Two hundred gastrointestinal stromal
tumors: Recurrence patterns and prognostic factors
for survival. Ann Surg. 2000; 231(1): 51-58.
3. Lv M, Wu C, Zheng Y, Zhao N. Incidence and survival
analysis of gastrointestinal stromal tumors in
Shanghai: A population-based study from 2001 to
2010. Gastroenterol Res Pract. 2014; 2014: 83416
4. Pisani P, Parkin DM, Bray F, Ferlay J. Estimates of
the worldwide mortality from 25 cancers in 1990. Int
J Cancer. 1999; 83(1): 18-29.
5. Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers
C, Rebelo M, et al. Cancer incidence and mortality
worldwide: sources, methods and major patterns
in GLOBOCAN 2012. Int J Cancer. 2015; 136(5):
E359-E386.
6. Zhao X, Yue C. Gastrointestinal stromal tumor. J
Gastrointest Oncol. 2012; 3(3): 189-208. 7. ESMO/European Sarcoma Network Working Group.
Gastrointestinal stromal tumors: ESMO Clinical
Practice Guidelines for diagnosis, treatment and follow-
up. Ann Oncol. 2012; 23(Suppl 7): vii49-vii55.
8. Lux ML, Rubin BP, Biase TL, Chen CJ, Maclure T,
Demerti G, et al. KIT extracellular and kinase domain
mutations in gastrointestinal stromal tumors. Am J
Pathol. 2000; 156(3): 791-795.
9. Heinrich MC, Corless CL, Demetri GD, Blanke CD,
von Mehren M, Joensuu H, et al. Kinase mutations
and imatinib response in patients with metastatic
gastrointestinal stromal tumor. J Clin Oncol. 2003;
21(23): 4342-4349.
10. Duffy MJ, Lamerz R, Haglund C, Nicolini A,
Kalousová M, Holubec L, et al. Tumor markers in
colorectal cancer, gastric cancer and gastrointestinal
stromal cancers: European group on tumor markers
2014 guidelines update. Int J Cancer. 2014; 134(11):
2513-2522.
11. Heinrich MC, Corless CL, Duensing A, McGreevey
L, Chen C-J, Joseph N, et al. PDGFRA activating
mutations in gastrointestinal stromal tumors. Science.
2003; 299(5607): 708-710.
12. Moutinho C, Mateus AR, Milanezi F, Carneiro F,
Seruca R, Suriano G. Epidermal growth factor receptor
structural alterations in gastric cancer. BMC
Cancer. 2008; 8(10): 10.
13. Cohen RB. Epidermal growth factor receptor as a
therapeutic target in colorectal cancer. Clin Colorectal
Cancer. 2003; 2(4): 246-251.
14. Yarden Y. The EGFR family and its ligands in human
cancer. Signalling mechanisms and therapeutic opportunities.
Eur J Cancer. 2001; 37(Suppl 4): S3-S8.
15. Voldborg BR, Damstrup L, Spang-Thomsen M,
Poulsen HS. Epidermal growth factor receptor (EGFR)
and EGFR mutations, function and possible role in
clinical trials. Ann Oncol. 1997; 8(12): 1197-1206.
16. Yamaoka T, Ohba M, Ohmori T. Molecular-targeted
therapies for epidermal growth factor receptor and its resistance
mechanisms. Int J Mol Sci. 2017; 18(11): 2420.
17. Edris B, Espinosa I, Mühlenberg T, Mikels A, Lee
CH, Steigen SE, et al. ROR2 is a novel prognostic
biomarker and a potential therapeutic target in leiomyosarcoma
and gastrointestinal stromal tumour. J
Pathol. 2012; 227(2): 223-233.
18. Rubin BP, Heinrich MC, Corless CL. Gastrointestinal
stromal tumour. Lancet. 2007; 369(9574): 1731-1741.
19. Hynes NE, Lane HA. ERBB receptors and cancer:
The complexity of targeted inhibitors. Nat Rev
Cancer. 2005; 5(5): 341-354.
20. Jiang Z, Li C, Li F, Wang X. EGFR gene copy number
as a prognostic marker in colorectal cancer patients
treated with cetuximab or panitumumab: A systematic
review and meta analysis. PLoS One. 2013; 8(2):
e56205.
21. Temel S, Uren D, Yakicier MC. Genetics and molecular
basis of gastric cancer. In: Canbay E, Zilberstein B,
Sossai P, Jinjuvadia K, Catterjee I, Editors. Overview
on Gastric Cancer, 3rd ed. Las Vegas, NV, USA: Open
Access eBooks. 2018: 1-13.
22. Metro G. EGFR targeted therapy for lung cancer:
are we almost there? Transl Lung Cancer Res. 2018;
7(Suppl 2): S142-S145.
23. Ergin K, Gürsoy E, Başimoǧlu Koca Y, Başaloǧlu H,
Seyrek K. Immunohistochemical detection of insulin-
like growth factor-I, transforming growth factorbeta2,
basic fibroblast growth factor and epidermal
growth factor-receptor expression in developing rat
ovary. Cytokine. 2008; 43(2): 209-214.
24. Shi S-S, Wu N, He Y, Wei X, Xia Q-Y, Wang X, et
al. EFGR gene mutation in gastrointestinal stromal
tumors. Histopathology. 2017; 71(4): 553-561.
25. Apicella M, Corso S, Giordano S. Targeted therapies
for gastric cancer: Failures and hopes from clinical
trials. Oncotarget. 2017; 8(34): 57654-57669.
26. Cancer Genome Atlas Research Network. Comprehensive
molecular characterization of gastric adenocarcinoma.
Nature. 2014; 513(7517): 202-209.
27. Huss S, Künstlinger H, Warderlmann E, Kleine MA,
Binot E, Merkelbach-Bruse S, et al. A subset of gastrointestinal
stromal tumors previously regarded as
wild-type tumors carries somatic activating mutations
in KIT exon 8 (pD419del). Mod Pathol. 2013; 26(7):
1004-1012.
|
|
|
|
 |
Number 27
VOL. 27 (2), 2024 |
Number 27
VOL. 27 (1), 2024 |
Number 26
Number 26 VOL. 26(2), 2023 All in one |
Number 26
VOL. 26(2), 2023 |
Number 26
VOL. 26, 2023 Supplement |
Number 26
VOL. 26(1), 2023 |
Number 25
VOL. 25(2), 2022 |
Number 25
VOL. 25 (1), 2022 |
Number 24
VOL. 24(2), 2021 |
Number 24
VOL. 24(1), 2021 |
Number 23
VOL. 23(2), 2020 |
Number 22
VOL. 22(2), 2019 |
Number 22
VOL. 22(1), 2019 |
Number 22
VOL. 22, 2019 Supplement |
Number 21
VOL. 21(2), 2018 |
Number 21
VOL. 21 (1), 2018 |
Number 21
VOL. 21, 2018 Supplement |
Number 20
VOL. 20 (2), 2017 |
Number 20
VOL. 20 (1), 2017 |
Number 19
VOL. 19 (2), 2016 |
Number 19
VOL. 19 (1), 2016 |
Number 18
VOL. 18 (2), 2015 |
Number 18
VOL. 18 (1), 2015 |
Number 17
VOL. 17 (2), 2014 |
Number 17
VOL. 17 (1), 2014 |
Number 16
VOL. 16 (2), 2013 |
Number 16
VOL. 16 (1), 2013 |
Number 15
VOL. 15 (2), 2012 |
Number 15
VOL. 15, 2012 Supplement |
Number 15
Vol. 15 (1), 2012 |
Number 14
14 - Vol. 14 (2), 2011 |
Number 14
The 9th Balkan Congress of Medical Genetics |
Number 14
14 - Vol. 14 (1), 2011 |
Number 13
Vol. 13 (2), 2010 |
Number 13
Vol.13 (1), 2010 |
Number 12
Vol.12 (2), 2009 |
Number 12
Vol.12 (1), 2009 |
Number 11
Vol.11 (2),2008 |
Number 11
Vol.11 (1),2008 |
Number 10
Vol.10 (2), 2007 |
Number 10
10 (1),2007 |
Number 9
1&2, 2006 |
Number 9
3&4, 2006 |
Number 8
1&2, 2005 |
Number 8
3&4, 2004 |
Number 7
1&2, 2004 |
Number 6
3&4, 2003 |
Number 6
1&2, 2003 |
Number 5
3&4, 2002 |
Number 5
1&2, 2002 |
Number 4
Vol.3 (4), 2000 |
Number 4
Vol.2 (4), 1999 |
Number 4
Vol.1 (4), 1998 |
Number 4
3&4, 2001 |
Number 4
1&2, 2001 |
Number 3
Vol.3 (3), 2000 |
Number 3
Vol.2 (3), 1999 |
Number 3
Vol.1 (3), 1998 |
Number 2
Vol.3(2), 2000 |
Number 2
Vol.1 (2), 1998 |
Number 2
Vol.2 (2), 1999 |
Number 1
Vol.3 (1), 2000 |
Number 1
Vol.2 (1), 1999 |
Number 1
Vol.1 (1), 1998 |
|
|
